Key result
Prophylactic carvedilol prevented the significant reduction in left ventricular ejection fraction seen with placebo (P<0.001) in women undergoing anthracycline therapy for breast cancer.
Why the study?
Does carvedilol prevent anthracycline-induced cardiotoxicity in women with recently diagnosed breast cancer undergoing anthracycline therapy?
RCT (n=91)
Single-blind
Randomly assigned
Does carvedilol prevent anthracycline-induced cardiotoxicity in women with recently diagnosed breast cancer undergoing anthracycline therapy?
p-value: p=<0.001
Prophylactic use of carvedilol preserves left ventricular systolic and diastolic function and reduces myocardial necrosis markers in women undergoing anthracycline chemotherapy for breast cancer.
No takes yet. Share an insight, caveat, or question.
Supports prophylactic carvedilol to preserve LVEF during anthracycline therapy in breast cancer; confirms RCT benefit for cardiotoxicity prevention.
Nabati et al. (2017) conducted an RCT in Breast cancer undergoing anthracycline therapy (n=91). Carvedilol vs. Placebo was evaluated on Absolute changes in mean left ventricular ejection fraction, end diastolic volume, and end systolic volume (p=<0.001). Prophylactic carvedilol prevented the significant reduction in left ventricular ejection fraction seen with placebo (P<0.001) in women undergoing anthracycline therapy for breast cancer.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: